4D Molecular Therapeutics CEO David Kirn disposes of common shares worth $1,068,651.63
FDMT•CEO share sale and option exercise
- 4D Molecular Therapeutics CEO David Kirn sold 69,076 shares on Aug. 19, 2026 at weighted average prices of $15.36 to $16.42.
- He exercised options to acquire 50,000 shares at $4.14 on the same day.
- Kirn’s direct holding ended the day at 825,819 shares.
